Kevin Wymer, MD
Urology · Rochester, MNNPI 1770947434
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,071 of the $16,016 with a category attached, or 62.9%. 7 manufacturers reported payments, led by Boston Scientific at 55.2% of the total. 2025 is the largest year on record at $9,052, more than ten times the $250 reported in 2019. Among urology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $291.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$9K
- Johnson & Johnson$5K
- Calyxo, Inc.$2K
- KARL Storz Endoscopy-america$80
- Procept Biorobotics Corporation$59
- Bayer$57
- plus $20 from 1 others
What the payments were for
- Consulting fees$10,07163%
- Travel & lodging$3,28020%
- Food & beverage$2,66517%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 30 | $8,845 |
| Johnson & Johnson | 9 | $4,805 |
| Calyxo, Inc. | 11 | $2,150 |
| KARL Storz Endoscopy-america | 2 | $80 |
| Procept Biorobotics Corporation | 1 | $59 |
| Bayer | 1 | $57 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$6,616
- Monarch Platform$4,621
- CVAC Aspiration System$2,026
- GENERAL - THERAPIES$425
- Lumenis Pulse 120H$240
- LithoVue$237
- SpaceOAR VUE System - 10mL$142
- ACCOLADE SR$107
How this compares
$16,016 in reported general payments places this provider in the 90th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 14 | $8,548 |
| Tamsulosin Hcl | 22 | $527 |
| Trospium Chloride | 15 | $462 |
| Finasteride | 17 | $321 |
Paid to pharmacies, not to this prescriber.
Other urology in Rochester
- Jonathan WarnerRochester$144K
- Tobias KohlerRochester$89K
- Stephen BoorjianRochester$61K
- Robert KarnesRochester$29K
- Paras ShahRochester$14K
- Matthew ZiegelmannRochester$9K
- Meghan CooperRochester$8K
- Sevann HeloRochester$6K
- Brian LinderRochester$6K
- Aaron PotretzkeRochester$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.